Remdesivir

remdesivir is one of four arms in a WHO-sponsored Bundibugyo ebolavirus treatment trial in Ituri Province, Democratic Republic of Congo, which dosed its first patient on 2 July 2026 after DRC and Uganda regulators cleared the protocol that had stalled it since late May . Patients are randomised to supportive care alone, supportive care plus remdesivir, plus the antibody cocktail MBP134, or both together, with a separate obeldesivir Arm testing post-exposure prophylaxis; the primary endpoint is 28-day survival across an estimated 1,000 participants. The trial is run jointly by WHO, DRC's national biomedical research institute (INRB), Oxford University and the Antwerp Institute of Tropical Medicine.

remdesivir is an antiviral medicine developed by Gilead Sciences that works by interfering with viral RNA replication. It was originally investigated as a treatment for hepatitis c and Ebola but gained global recognition during the COVID-19 pandemic, becoming the first antiviral authorised by the US FDA (October 2020) and EU regulators for treating COVID-19 in hospitalised patients. Under the brand name Veklury, it was used in millions of patients worldwide during the pandemic. Its COVID-19 benefit was most clearly demonstrated in patients who received supplemental oxygen, with evidence of reducing hospital stay by several days in controlled trials.

The Bundibugyo study is remdesivir's most prominent Ebola application since early-phase trials before the pandemic, and dosing its first patient makes it the drug's first real-world test against this species rather than a paper candidate. If the trial demonstrates efficacy, it would extend remdesivir's established safety profile into Ebola treatment, potentially providing an accessible off-patent-adjacent option in resource-constrained settings where bespoke antibody treatments can be difficult to obtain. The trial design, running remdesivir alongside MBP134 rather than as a standalone Arm, reflects a combination-therapy hypothesis common in antiviral research.